| Q42580878 | A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice |
| Q46461310 | Acoustic change complex in background noise: phoneme level and timing effects |
| Q30396028 | Auditory evoked fields measured noninvasively with small-animal MEG reveal rapid repetition suppression in the guinea pig. |
| Q33982857 | Auditory sensory gating in the neonatal ventral hippocampal lesion model of schizophrenia |
| Q48419162 | Changes in mid-to-late latency auditory evoked responses in the chicken during neural maturation. |
| Q46670466 | Corticosterone modulates auditory gating in mouse |
| Q90236810 | Destruction of ERP responses to deviance in an auditory oddball paradigm in amyloid infusion mice with memory deficits |
| Q46730772 | Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice |
| Q80826340 | Early auditory sensory processing deficits in mouse mutants with reduced NMDA receptor function |
| Q37846896 | Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia |
| Q48363989 | Impaired attentional modulation of auditory evoked potentials in N-methyl-D-aspartate NR1 hypomorphic mice |
| Q30493152 | In vitro and in vivo demonstration of risperidone implants in mice. |
| Q36706331 | In vivo functions of mitogen-activated protein kinases: conclusions from knock-in and knock-out mice |
| Q45937104 | Ketamine modulates theta and gamma oscillations. |
| Q30436342 | Knockout of NMDA receptors in parvalbumin interneurons recreates autism-like phenotypes. |
| Q35823293 | MeCP2+/- mouse model of RTT reproduces auditory phenotypes associated with Rett syndrome and replicate select EEG endophenotypes of autism spectrum disorder |
| Q35793568 | Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma |
| Q36602511 | Memantine Improves Attentional Processes in Fragile X-Associated Tremor/Ataxia Syndrome: Electrophysiological Evidence from a Randomized Controlled Trial |
| Q30469318 | Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients. |
| Q39733668 | Miniature neurologgers for flying pigeons: multichannel EEG and action and field potentials in combination with GPS recording |
| Q30391868 | Modulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats |
| Q33885925 | Mouse model predicts effects of smoking and varenicline on event-related potentials in humans |
| Q42242034 | NMDA antagonist MK801 recreates auditory electrophysiology disruption present in autism and other neurodevelopmental disorders. |
| Q41818221 | NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia |
| Q30432782 | NR2B Antagonist CP-101,606 Abolishes Pitch-Mediated Deviance Detection in Awake Rats |
| Q30403302 | Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate |
| Q30486447 | Neurophysiological biomarkers for drug development in schizophrenia |
| Q28728978 | Nicotine receptor subtype-specific effects on auditory evoked oscillations and potentials |
| Q48374404 | Noradrenergic antagonism of the P13 and N40 components of the rat auditory evoked potential |
| Q30478352 | Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism |
| Q46309086 | Role of beta2-containing nicotinic acetylcholine receptors in auditory event-related potentials |
| Q30354621 | Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models. |
| Q64068178 | Trace Amine-Associated Receptor 1 Agonist Modulates Mismatch Negativity-Like Responses in Mice |
| Q35739457 | Translating glutamate: from pathophysiology to treatment |